TherapeuticsMD (TXMD) Total Current Liabilities (2010 - 2026)

TherapeuticsMD's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• Quarterly Total Current Liabilities rose 3.59% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 3.59% YoY) and the FY2025 annual result came in at $4.8 million, down 7.38% from the prior year.
• Total Current Liabilities was $4.9 million for Q1 2026 at TherapeuticsMD, up from $4.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $264.8 million in Q1 2022 and bottomed at $4.7 million in Q2 2025.
• A 5-year average of $44.3 million and a median of $6.5 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 332.14% — and 2023, when it sank 92.7%.
• TherapeuticsMD's Total Current Liabilities stood at $46.8 million in 2022, then sank by 85.37% to $6.9 million in 2023, then dropped by 24.63% to $5.2 million in 2024, then retreated by 7.38% to $4.8 million in 2025, then climbed by 2.63% to $4.9 million in 2026.
• Business Quant data shows TXMD's Total Current Liabilities at $4.9 million in Q1 2026, $4.8 million in Q4 2025, and $4.9 million in Q3 2025.